000 01221 a2200361 4500
005 20250516141707.0
264 0 _c20140227
008 201402s 0 0 eng d
022 _a1365-2710
024 7 _a10.1111/jcpt.12058
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aOztekin, O
245 0 0 _aChemotherapy for transient myeloproliferative disorder in a premature infant with Down syndrome.
_h[electronic resource]
260 _bJournal of clinical pharmacy and therapeutics
_cJun 2013
300 _a262-4 p.
_bdigital
500 _aPublication Type: Case Reports; Journal Article
650 0 4 _aAntineoplastic Agents
_xtherapeutic use
650 0 4 _aDown Syndrome
_xcomplications
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aInfant, Newborn
650 0 4 _aInfant, Premature
650 0 4 _aMyeloproliferative Disorders
_xdiagnosis
700 1 _aKalay, S
700 1 _aTezel, G
700 1 _aTayfun, F
700 1 _aKupesiz, A
700 1 _aHangul, M
700 1 _aAkcakus, M
700 1 _aOygur, N
773 0 _tJournal of clinical pharmacy and therapeutics
_gvol. 38
_gno. 3
_gp. 262-4
856 4 0 _uhttps://doi.org/10.1111/jcpt.12058
_zAvailable from publisher's website
999 _c22597030
_d22597030